QMS Nº: ODG/FMT/049

Rev. Nº: 0

Effective date: 02/02/2021 Ref. Doc.: QMS /MAN /002



Rwanda Food and Drugs Authority

Nyarutarama Plaza KG 9 Avenue Email: info@rwandafda.gov.rw; website: www.rwandafda.gov.rw

MINUTES OF THE MEETING No:/...../FDA/2021 FOR PEER REVIEW

Date of Meeting: 17/06/2021

Venue of the meeting: Virtual

Attendance List (Hard copy to be by a hand-signed and attached on these minutes)

S/Nº	Names	Position
1.	Dr.Eric NYIRIMIGABO	Division Manager of Human Medicine and Devices Assessment and Registration
2.	Dr.Rosine MANISHIMWE	Division Manager of Veterinary Medicine Devices and Assessment and Registration
3.	Dr.Janvier MUKIZA	Division Manager of Cosmetics and Household Chemicals Assessment and Registration
4.	Dr.Doreen INGABIRE	Veterinary Medicines in Vitro Diagnostics and Medical Devices Registration Analyst
5.	Dr.Richard HABIMANA	Vaccines and Biosimilar Registration Analyst
6.	Clarisse IRASABWA	Finished and Active Pharmaceutical Products Registration Analyst
7.	Deo GASANA	Finished and Active Pharmaceutical Products Registration Analyst
8.	Tite UWAMBAJINEZA	Radiopharmaceuticals and Radiotherapy Products Assessment and Registration Analyst
9.	Dr.Emil Ivan MWIKARAGO	Diagnostics and Medical Devices Registration Analyst
10.	Jurdas SEZIRAHIGA	Public Health and Laboratory Chemicals Registration Analyst
11.	Honore AYINKAMIYE	Ag Finished and Active Pharmaceutical Products Registration Specialist
12.	Marie Ange ISINGIZWE	Ag Finished and Active Pharmaceutical Products Registration Specialist
13.	Nadine NIYOMAHORO	Ag Finished and Active Pharmaceutical Products Registration Specialist
14.	Anitha TUYISHIME	Ag Herbal Medicines Assessment and Registration Specialist



QMS Nº: ODG/FMT/049

Rev. Nº: 0

Effective date: 02/02/2021 Ref. Doc.: QMS /MAN /002

15.	Ruth MUHONGERWA	Ag Herbal Medicines Assessment and Registration Specialist
16.	Dr. Placide MUHAYIMANA	Ag Diagnostics and Medical Devices Registration Specialist
17.	Serge SHYIRAMBERE	Ag Vaccines and Biosimilar Registration Specialist
18.	Damascene DUSABIMANA	Ag Vaccines and Biosimilar Registration Specialist
19.	Olivier MURERAMANZI	Ag Biological Products Registration Specialist
20.	Diane ITETERE	Ag Biological Product Registration Specialist
21.	Geoffrey KARASANYI	Ag Veterinary Medicines Registration and Variation Assessment Specialist
22.	Nadia UWERA	Ag Veterinary Medicines Registration and Variation Assessment Specialist
23.	Felix TUYISENGE	AgVeterinary in vitro Diagnostics and Medical Devices Registration Specialist
24.	Patrick GAD IRADUKUNDA	Ag Cosmetics Registration Specialist
25.	Leodomir NIYITEGEKA	Ag Cosmetics Registration Specialist
26.	Gentille MASENGESHO	Ag Public Health and Laboratory Chemicals Registration Specialist
27.	Innocent UWOROHEJE	Ag Veterinary Medicines Testing Officer
28.	Jean Pierre NSANZIMFURA	Ag Cosmetic Testing Officer
29.	Janvier MUNYANEZA	Ag Pesticides Testing Officer
30.	Jackson KARARA	Ag Food and Drugs Port of Entry Inspection Specialist
31.	Jeremie NTEZIYAREMYE	Industrial and Market Specialist

Item on the agenda

Presenting final dossier assessment reports of Human medicines products, Antiseptics and disinfectants products to the Peer review committee for approval (27 Products).

Opening and/or remarks of the meeting

The meeting started at 03:05 pm with the opening remarks of the Division Manager of Human Medicine and Devices Assessment and Registration, Dr. Eric Nyirimigabo who introduced the participants and presented the agenda of the meeting.





	Discussion	Observation	Resolutions/ recommendation	Presenter	Timelines
	FASTUM GEL with reference	FASTUM GEL is a gel of	Based on the information from the	Jean Pierre	Done
	by MENARINI Industry Farmaceutiche riunite S.R.I was presented and had queries, where the applicant has well responded to all queries raised in addition, have applied for GMP inspection and paid	colorless or almost transparent, with an aromatic odour. The initial application was assessed through full assessment with the outcome of "additional data requested" for the first	agreed upon that the safety and efficacy were supported and the product was recommended for registration.	A Committee of the Comm	
	applied for GMP inspection and paid the prescribed fees.	round. It was observed that all queries have been resolved by the applicant.			
	EASCOF EXPECTORANT manufactured by Cachet Pharmaceuticals PVT LTD was	EASCOF EXPECTORANT is an Orange-yellow colour clear liquid having sweet taste and	Based on the information from the assessment report, it has been that the safety and	Jean Pierre Nsanzimfura.	Done
\mathcal{U}	presented and responded well to the queries, in addition, have applied	pleasant flavour manufactured. The initial application was	efficacy were supported and the product was recommended for		
	for GMP inspection and paid the prescribed fees.	assessed through full assessment with the outcome of "additional			
		data requested" for the first round. It was observed that all queries have been resolved by the	DA FDA		
	SOMAZINA 1000MG ORAL	SOMAZINA 1000MG ORAL	Somazina 1000mg oral solution	Tean Pierre	Done
	with refe	SOLUTION is an oral solution	d the registra	ızimfura	
	manufactured by FERRER	Internacional.S. A. The initial	recommended for registration		
	was presented and responded well to	application has been assessed			

GAMALATE B6 ORAL SOLUTION with reference number 1835/2018 &2232 and manufactured by FERRER INTERNATIONAL S.A/SPAIN was presented and responded well to the queries. Furthermore, an application for GMP inspection was done and the prescribed fees was paid.	application for GMP inspection was done and the prescribed fees were paid. GAMALATE (TABLETS) with reference number 1830/2018 & 2231/2019 and manufactured by FERRER INTERNATIONAL S.A/SPAIN was presented and responded well to the queries. Furthermore, an application for GMP inspection was done and the prescribed fees was paid.
GAMALATE B6 ORAL SOLUTION is a viscous orange liquid with characteristics of odour and taste manufactured by Ferrer Internacional S.A. The initial application has been assessed through full assessment procedure with the outcome of additional data at the first round which were fully responded to support the quality, safety and efficacy of the product.	procedure with the outcome of additional data at the first round which was fully responded to support the quality, safety and efficacy of the product. GAMALATE (TABLETS) is blue sugar-coated tablet. The initial application has been assessed through full assessment procedure with the outcome of additional data at the first round which were fully responded to support the quality, safety and efficacy of the product.
Gamalate Syrup has fulfilled the registration requirement and was recommended for registration.	Gamalate Tablets has fulfilled the registration requirement and was recommended for registration
Jean Pierre Nsanzimfura	Jean Pierre Nsanzimfura
Done	Done

QMS N : ODG/FM1/049
Rev. N°: 0
Effective date: 02/02/2021
Ref. Doc.: QMS /MAN /002



sul rea va Th to pa it ma 安岛 B B B B

	Shyirambere	with condition will be issued	pale yellow to colorless liquid free from particles that can be	676/2018 by
Done	Serge	The product is recommended	BEVAAS-400 is a clear and	BEVAAS-400 with reference
				payment.
				SUSD less to the presumed
				nade was 4985USD implying
			15USD on GMP inspection fees.	t was noted that a payment fee
			about the remaining amount of	pay the prescribed fees, however,
			communicate to the applicant	o apply for GMP inspection and
			the office of finance to	The applicant was also requested
			recommended that liaise with	validation protocol and report.
			requirements and it was	eadable documents of process
			product fulfilled other	submission of openable and
			Biopharma Limited. The	he queries regarding the
			manufactured by Hetero	applicant sufficiently responded to
		arter payment of 1505D.	observed by visual inspection	BIOPHARMA/INDIA. The
		i.e. the certificate will be issued	free from particles that can be	nanufactured by HETERO
	Shyirambere		pale yellow to colorless liquid	number 677/2018 and
Done	Serge	=	BEVAAS-100 is a clear and	S-10



×

			was recommended.	
			is on GMF inspection tees	
			1 ST ISD and OM important from	
			about the missing amount of	
			to communicate to the applicant	
		пи рида сминить	Liaise with the office of finance	4985USD.
		Deliver Andrews		that the payment fee made was
			safety.	by applying however, it was noted
			queries related to quality and	whereby the applicant responded
			sufficiently responded to the	GMP inspection application
n '		X	LUPRODEX 3.5MG (DEPOT)	queries included a query on the
			Limited. Application for	the queries. Among the raised
			Bharat Serum&Vaccines	presented and responded well to
		15USD	Injection manufactured by	Serum & Vaccines Limited was
		i.e. the c	for	and manufactured by Bharat
	Shyirambere	for registration with the	(DEPOT) is White to off White	with reference number 1124/2019
Done	Serge	product was recommended	LUPRODEX 3.5MG	LUPRODEX 3.5MG (DEPOT)
			8	was paid.
		~	justify SEQ.	was done and the prescribed fees
			satisfied the requirements to	application for GMP inspection
			Limited that has sufficiently	to the queries. Furthermore, an
			Stanford Laboratories Private	was presented and responded well
			both sides manufactured by	Laboratories Private Limited.
			biconvex coated tablets plain on	manufactured by Stanford
	Shyirambere	for registration on condition.	off white circular shaped	number 13973/2018 and
Done	Serge	The product was recommended	SEVLAREN 400 is a white to	SEVLAREN 400 with reference
			TITLE IS THE CONTROL OF THE CONTROL	
			was made to this product as well	
			15USD on GMP inspection fees	
	THE RESERVE THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TWIND TWO IS NAMED IN COLUMN TWO IS NAMED IN COLUMN TWO IS NAMED IN			

(4)	
W)
(4)	
M	

	y	
DRIED with reference number 2988/2016 and manufactured by Serum Institute, India. The application was presented in the previous peer review meeting with		number 3038/2019 and manufactured by Lincoln Pharmaceuticals Limited, India was presented and responded well to the queries. Furthermore, an application for GMP inspection was done and the prescribed fees was paid.
DRIED is manufactured by Serum Institute, India. The application for GMP has been cleared.	Notice: The first assessment of VASTEN-75 was done in green color instead of red as per presumed in the SOP. This was an internal arrangement for the new staffs to be familiarized with an assessment before getting training on dossier assessment. There are other documents that have been assessed in the same manner.	white coloured, round-shaped, flat, uncoated tablet, break line on one side and plain on other side manufactured by Lincoln Pharmaceuticals Limited, India. The application complied with safety, efficacy and quality requirements.
The product was recommended for registration		ine product was recommended for registration
nmended		ended
nmended Nadine Niyomahoro		Shyirambere

QM5 N : ODG/FM1/049
Rev. N°: 0
Effective date: 02/02/2021
Ref. Doc.: QM5 /MAN /002



			It has complied with registration requirement including paying and	prescribed fees was paid.	_
			the second round of additional data.	GMP inspection was done and the	
			This was a second assessment of	Furthermore, an application for	
			Laboratorio Aldo-Union, S. L.	and responded well to the queries.	
			after agitation manufactured by	Aldo-Union, S.L was presented	
		and Drugs Authority	suspension with an orange odour	manufactured by Laboratorio	
			almost white and homogeneous	number 14386/2018 and	
	Niyomahoro	for registration	SUSPENSION is a white or	SUSPENSION with reference	
Done	Nadine	The product was recommended	PAIDOFEBRIL ORAL	PAIDOFEBRIL ORAL	
				application for GMP inspection.	
		X		the remaining query of the	
			The second secon	previous peer review meeting with	l!
			been cleared.	application was presented in the	
			The application for GMP has	Serum Institute, India. The	
			Institute, India	4778/2019 and manufactured by	
	Niyomahoro	for registration	manufactured by Serum	reference number 21494/2015 &	
Done	Nadine	The product was recommended	REPOITIN IU PFS is	REPOITIN IU PFS with	
			<	for GMP inspection.	
				remaining query of the application	
				review meeting with the	
			been cleared.	was presented in the previous peer	
			The application for GMP has	Institute, India. The application	
			Serum Institute, India	manufactured by Serum	
			DRIED is manufactured by	number 8089/2016 and	
	Niyomahoro	for registration	ATTENUATED, FREEZE	ATTENUATED with reference	
Done	Nadine	The product was recommended	MEASLES VACCINE LIVE	MEASLES VACCINE LIVE	
				application for GMF inspection.	
				the remaining query of the	
The state of the s					

QMS N: ODG/FM1/049
Rev. Nº: 0
Effective date: 02/02/2021
Ref. Doc.: QMS /MAN /002

X	
reference number 0773/2019 and manufactured by TAKEDA IRELAND LTD/IRELAND was presented and responded well to the queries. Furthermore, an application for GMP inspection was done and the prescribed fees was paid.	TAPROS 3.75 with reference number 1172/2019 and manufactured by TAKEDA IRELAND LTD/IRELAND was presented and responded well to the queries. Furthermore, an application for GMP inspection was done and the prescribed fees was paid.
pale yellow, oblong, biconvex, film-coated tablet with "12.5/1000" debossed on one side and "322M" debossed on the other side manufactured by Takeda Pharmaceutical Company Limited. Application of Vipidomet 12.5&1000 passed first and second assessment at the first round of additional data and has shown to comply with registration requirement including paying and applying for GMP inspection at Rwanda FDA.	applying for GMP inspection at Rwanda FDA. TAPROS 3.75 is a human medicinal product manufactured by Takeda Pharmaceutical Company Limited. The application passed the first round second assessment at the first round of additional data and has complied with registration requirement including paying and applying for GMP inspection at Rwanda FDA.
for registration	The product was recommended for registration
Karasanyi	Geoffrey Karasanyi
Done	Done

QMS N: ODG/FM1/049
Rev. N°: 0
Effective date: 02/02/2021
Ref. Doc.: QMS /MAN /002

presented and responded well to SERVIER 3805/2016.D; 3805/2016.B; and engraved with"10/5" on one face FDA was acknowledged. the queries. INDUSTRIES 3805/2016.C manufactured by reference number (3805/2016.A; | Triangular—shaped tablet, COVERAIM were presented: for GMP inspection by the Rwanda The application and proof of payment the following respective following COVERAM 10&10 COVERAM 5&5 COVERAM 5&10 COVERAM 10&5 strengths (IRELAND) | manufactured by Servier was (Ireland) Industries LTD of with"5/10" on one face and square-shaped tablet, engraved and 💝 on the other face COVERAM 10&5 is White COVERAM 10&10 is a white rod-shaped round-shaped tablet, engraved with"5/5" on one face and * by Servier (Ireland) Industries on the other face manufactured with"10/10" on one face and by Servier (Ireland) Industries on the other face manufactured (Ireland) Industries LTD manufactured by Servier COVERAM 5&5 is a white COVERAM 5&10 is a white on the other face tablet, engraved for registration The product was recommended Anitha Tuyishime Done

Rev. Nº: 0

Ref. Doc.: QMS /MAN /002 Effective date: 02/02/2021

A Company	×
\cup	

	U		
number 0774/2019 and manufactured by Takeda Ireland LTD was presented and responded well to the queries. Furthermore, an application for GMP inspection was done and the prescribed fees was paid.	prescribed fees was paid.	with reference number 16065/2017 and manufactured by Cachet Pharmaceuticals Private Limited was presented and responded well to the queries. Furthermore, an application for GMP inspection was done and the	
WIPIDIA-25 is a human medicinal product manufactured by Takeda Ireland LTD was assessed and the fact that all queries addressed were resolved.	The application complied with safety, efficacy and quality requirements including the application for GMP inspection however the product sample was not submitted	TRAMACETAL TABLETS is a yellow coloured, oblong, biconvex, film-coated tablets with a breakline on one side manufactured by Cachet Pharmaceuticals Private Limited.	All COVERAM branded product mentioned above passed the first and second assessment at the second round of additional data and has shown to comply with the registration requirement.
The product was recommended for registration.		The product was recommended for registration but after the submission of samples. Clarisse will follow up.	
Jean Pierre Nsanzimfura		Nadia Uwera	
Done		Done	

QMS N: ODG/FM1/049
Rev. N°. 0
Effective date: 02/02/2021
Ref. Doc.: QMS /MAN /002



Y

prescribed fees was paid. prescribed fees was paid. manufactured manufactured by CELLTRION disoproxil fumarate GMP inspection was done and the Furthermore, an application for reference number 2357/2019 and GMP inspection was done and the Furthermore, an application for responded well to the queries. PHARMA, reference number 8540/2020 and responded well to the queries. LTD/KENYA was presented and LABORATORY & ALLIED FOLIC ACID TABLETS with KOREA was presented and Lamivudine/Tenofovir INC./SOUTH with ģ TABLETS is a yellow, circular, requirements including the safety, efficacy and quality The application complied with Laboratory & Allied Ltd. sides manufactured biconvex tablet plain on both previous peer review where the and plain on the other side debossed with "C 0" on one side shape, film-coated tablets mg/300 mg is a white, oblong FOLIC ACID The product was presented in manufactured by Celltrion, Inc. disoproxil fumarate specification number, this has container is not recommended. remaining query was to clarify pack size of 1000's in HDPE not submitted and the proposed application for GMP inspection been well clarified. LTR for sample submission and It has been agreed to contact however the product sample was Lamivudine/Tenofovir difference in 5MG bу for registration on condition to specify if the accepted container up. will be used and samples will be The product was recommended for registration. submitted. Clarisse will follow The product was recommended | Muhayimana Dr. Honore Ayinkamiye

Placide

Done



	revision of the pack size to less			
	than 90's in the HDPE container.			
SEKROL SYRUP with reference	SEKROL SYRUP is a Clear,	The product was recommended	Ruth	Done
number 3096/2019 and	colourless, cherry odoured	for registration.	Muhongerwa	
manufactured by Bilim Ilaç	Syrup manufactured by Bilim			
Sanayi ve Ticaret A.Ş was	Ilaç Sanayi ve Ticaret A.Ş. The			
presented and responded well to	application complied with			
the queries. Furthermore, an	safety, efficacy and quality			
application for GMP inspection	requirements moreover, the			
was done and the prescribed fees	applicant has applied for GMP			
was paid.	inspection.		6	
EVOKE TABLETS with	EVOKE TABLETS is a Blue	The product was recommended	Ruth	Done
reference number 2904/2019 and	diamond shaped biconvex film-	for registration.	Muhongerwa	
manufactured by Laboratory &	coated tablets plain on both sides			
Allied Ltd was presented and	manufactured by Laboratory &			
responded well to the queries.	Allied Ltd.			
Furthermore, an application for	The application complied with	X		
GMP inspection was done and the	safety, efficacy and quality			
prescribed fees was paid.	requirements including the			
	application for GMP inspection.	DATUA		
PAUSE-500 TABLETS with	PAUSE-500 TABLETS is	The product was recommended	Dr.Eustache	Done
reference number 1801/2019 and	White coloured circular	for registration.	Musafiri	
manufactured by Emcure	biconvex film-coated tablet			
Pharmaceuticals LTD was	manufactured by Emcure			
presented and responded well to	Pharmaceuticals LTD.			
the amount of Providence of the				

the queries. Furthermore, an

 \sim

application for GMP inspection The application complied with was done and the prescribed fees safety, efficacy and quality was paid. requirements including the application for GMP inspection.

Rev. N°: 0

Effective date: 02/02/2021

Ref. Doc.: QMS /MAN /002

Report of the second livings Authority

QMS N°: ODG/FMT/049 Rev. N°: 0

Effective date: 02/02/2021 Ref. Doc.: QMS/MAN/002

Names and signature Names, and signature and/or institution stamp Chair of the Dr. Eric NYIRIMIGABO Marie Ange ISINGIZWE meeting Rapporteur

The meeting has ended on: 17th June 2021 at **08h10 PM**


End of Minutes



QMS Nº: ODG/FMT/049 Rev. Nº: 0

Effective date: 02/02/2021 Ref. Doc.: QMS /MAN /002


ANNEX: Screenshots of the participants on Webex





Effective date: 02/02/2021 QMS 14°: 0 DG/FMT/049

Ref. Doc.: QMS /MAN /002



Page 17 of 17



